Resources

Tokyo, Japan, 5 August, 2025 - FRONTEO, Inc. and NICCA Chemical Co., Ltd. announced the launch of a co-creation project to explore novel targets in the cosmetics domain. This initiative leverages FRONTEO’s AI drug discovery support service, Drug Discovery AI Factory (“DDAIF”), to accelerate research and development of new products using effective cosmetic ingredients.

Tokyo, Japan, July 23, 2025 - FRONTEO, Inc. announced that, FRONTEO and the University of Oklahoma have begun a joint research project to explore new drug targets and drug repositioning, utilizing the unique technologies and research capabilities. This is the first step towards the development of FRONTEO's AI drug discovery business in the United States.

Tokyo, Japan, 9 July, 2025 -Fuji Pharma Co., Ltd. and FRONTEO, Inc.  today announced the launch of a co-creation project to evaluate drug discovery seeds, new drug candidates, in the field of women's health care, utilizing FRONTEO's AI drug discovery support service, Drug Discovery AI Factory (hereinafter "DDAIF").

Tokyo, Japan, 30 June, 2025 -Metagen Therapeutics, Inc. and FRONTEO, Inc. are pleased to announce the launch of a joint research collaboration applying the microbiome— an area of growing global attention—to drug discovery, using FRONTEO’s AI drug discovery support service, the “Drug Discovery AI Factory” (hereinafter “DDAIF”).

Tokyo, Japan, June 25, 2025 - FRONTEO, Inc. announced that it has signed a strategic partnership agreement with Q Partners LLC, a U.S. consulting firm with expertise in the life sciences industry.

Tokyo, Japan, 15 May, 2025 - FRONTEO, Inc. announces that it has commenced a collaborative project with Chugai Pharmaceutical Co., Ltd. to explore the use of AI technology for target discovery.

Tokyo, Japan, 13 May 2025 - FRONTEO, Inc. announced the launch of a joint research project with the National University Corporation Institute of Science Tokyo aimed at identifying new drug targets for multiple disease areas by leveraging the proprietary technologies of both organizations.